[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Grenoble\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":651},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,148,0,25,[9,45,83,111,134,164,186,210,237,257,281,317,344,371,389,410,429,451,475,502,529,555,582,605,633],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054293","evaluation-of-the-feasibility-and-efficacy-of-a-chronic-brain-computer-interface-for-speech-rehabilitation-in-patients-with-locked-in-syndrome-lis-100054293",false,"NCT07698496","Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)","SpeechBCI","Inclusion Criteria:\n\na. Male or female between 18 and 65 years old b. French speaking person c. Person in locked in syndrome with a severe speech disorder following either: i. A subcortical stroke ii. Amyotrophic Lateral Sclerosis. d. Person with stable clinical state (esp. regarding respiratory state) e. Person able to read on a screen (sufficient eye movement control) f. Negative plasma pregnancy test for women of childbearing potential\\* g. Highly effective or at least acceptable\\*\\* contraception for women of childbearing potential.\n\nh. Persistence of localizing signals of language function proven by functional MRI.\n\ni. Person able to perform a simple BCI task with MEG j. Person with a neuropsychological profile evaluated by psychiatrist as compatible with sustain BCI training k. Informed consent to participate in the obtained using their usual means and code of communication (residual vocalizations, eye-blinking code, pictograms, eye tracking, alphabet chart, etc.), in the presence of their trusted person or curator who is accustomed to communicating with them using this means.\n\nl. Person affiliated to the French social security system or beneficiary of such a system\n\nExclusion Criteria:\n\nPatients with any of the following criteria cannot be included in this investigation:\n\n1. Severe cognitive disorders assessed after a neuropsychological evaluation\n2. Deafness\n3. Continuous assisted ventilation\n4. Contraindication to intracranial surgery\n5. Contra-indication to MRI (1.5T), CT-scan or their related contrast agent injection or MEG examinations.\n6. Anatomical brain MRI showing structural abnormalities in the cortical areas of language\n7. Functional impairment of language cortical areas on MRI\n8. Auditory evoked potential showing hearing impairment\n9. Person with a skull shape incompatible with one WIMAGINE implant on each hemisphere\n10. Persons referred to in Articles L1125-7 of the Public Health Code and article 64 of MDR(corresponding to all protected persons: pregnant women, women in labor, breastfeeding mothers, minors, persons deprived of liberty by judicial or administrative decision.","ALL","18 Years","65 Years",{"count":21,"type":22},3,"ESTIMATED","INTERVENTIONAL",[25],"NA","Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment. In France, the Association du Locked-In Syndrome (ALIS) reports approximately 500 individuals with LIS, most of whom live at home. The quality of life of people with LIS depends strongly on their ability to communicate, and speech synthesis is the mode of communication restoration most desired by individuals with LIS. Several surveys have shown that improving communication abilities in these individuals leads to a significant improvement in their quality of life as well as that of their caregivers.\n\nNatural speech allows the production of an average of 150 words per minute. Non-invasive communication methods, whether based on residual motor function (eye-blink code) or on brain-machine or brain-computer interfaces (Brain-Computer Interface, BCI) using scalp electroencephalographic (EEG) signals, involve a high cognitive load and have low efficiency (spelling only a few letters per minute). Invasive BCIs for speech rehabilitation aim to overcome the limitations of non-invasive devices (cognitive overload and slow speech rate). The intention to act (the act of speaking) is predicted by an algorithm based on the direct decoding of neuronal activity from the sensorimotor cortex (the area where articulatory muscles are represented).\n\nTo date, studies testing speech rehabilitation BCIs in humans remain rare. A subdural electrocorticographic (ECoG) invasive BCI enabled speech decoding (words and sentences from a limited repertoire) for chronic use (2 years). Real-time control of an on-screen cursor allowing spelling of up to 90 letters per minute (equivalent to text messaging) has also been achieved using an intracortical invasive BCI (Utah Array). Very recently, up to 60 words per minute were produced using an intracortical invasive BCI (Utah Array) implanted in the ventral premotor cortex, although with a connector potentially contaminated by acoustic audio feedback. Furthermore, these devices still rely on transcutaneous connectors, which may be sources of infection and prevent routine daily-life use.\n\nIn summary, there is currently no fully implantable, wireless invasive \"speech BCI\" with real-time speech synthesis suitable for long-term home use. The present study will use an intracranial extradural invasive BCI combined with a speech synthesizer, with the aim of developing a communication tool suitable for everyday use. More specifically, the SpeechBCI protocol will propose two complementary BCI approaches in the same subject: a speech BCI (primary objective, BCI\\_PAROLE device) and a cursor BCI (secondary objective). Both BCIs will use the WIMAGINE intracranial epidural system, enabling ECoG signal acquisition with a very limited risk of infection and brain injury and providing signals that are more stable over time compared with intracortical or subdural ECoG devices that retain transcutaneous connectors. These systems will allow long-term and ecological use, as the WIMAGINE implant is wireless and offers excellent long-term signal stability. The WIMAGINE implant has already been successfully tested for controlling an exoskeleton in a tetraplegic subject (operational for over 6 years) and very recently for controlling walking in real-life conditions via a spinal cord stimulator in a paraplegic individual.\n\nThe BCI\\_PAROLE device will integrate a speech synthesizer providing real-time auditory feedback to the speaker. The BCI-CURSEUR device will allow the subject to control an on-screen cursor to access various communication functionalities (web access, emails, chats, etc.). This will provide a complementary communication solution to real-time speech production.\n\nThe hypothesis of this stydy is that the intention to speak (attempted speech) will be decoded by the BCI\\_PAROLE device in individuals with LIS because, as with limb paralysis, paralysis of articulatory and phonatory muscles does not prevent the corresponding cortical map from producing specific signals. Similarly, the BCI-CURSEUR device will decode the intention to move a cursor and perform actions on a computer screen.\n\nNeuronal electrical signals will be recorded bilaterally from the ventral motor cortex (representation of lips, cheeks, tongue, palate, and larynx-the vocal tract) and from the dorsal part of the motor cortex (larynx and hand, the latter for controlling a two-degree-of-freedom cursor), using a total of 128 electrodes (64 on each cerebral hemisphere). The implant will be optimally positioned over speech motor areas using preoperative functional imaging in order to optimize speech decoding by the BCI\\_PAROLE device.",[28,29],"Locked in Syndrome","ALS (Amyotrophic Lateral Sclerosis)",[31],"Locked in syndrom, Speech disorders, Brain-computer interface, BCI, speech rehabilitation","NOT_YET_RECRUITING","2026-07-07",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":22},"2026-10-10",{"date":40,"type":22},"2031-09-30",{"name":42,"class":43},"University Hospital, Grenoble","OTHER",4,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":73,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100054125","quality-of-life-of-patients-who-have-undergone-bilateral-mastectomy-100054125","NCT07699913","Quality of Life of Patients Who Have Undergone Bilateral Mastectomy","Psychological Experience, Quality of Life, and Patient Satisfaction Following Bilateral Breast Reconstruction After Prophylactic or Therapeutic Mastectomy, Using the BREAST-Q Questionnaire.","RM BREAST Q","Inclusion Criteria:\n\n* Female sex\n* Age ≥ 18 years\n* Bilateral mastectomy\n* Breast reconstruction between January 1, 2015, and January 1, 2026\n* No objection to the study\n\nExclusion Criteria:\n\n* Individual under guardianship or curatorship, or deprived of liberty\n* Reconstruction not completed by January 1, 2026.","FEMALE",{"count":55,"type":22},115,"OBSERVATIONAL","We therefore aim to determine whether the type of mastectomy (preventive in a high-risk patient or therapeutic in a patient with a history of cancer), as well as the timing (immediate or delayed) and type of breast reconstruction, influence the quality of life and satisfaction of patients who have undergone bilateral mastectomy. The goal of this observational study is thus to measure and compare the quality of life of patients who have undergone bilateral mastectomy using the BREAST-Q questionnaire.",[59,60,61,62,63,64,65,66,67,68,69,70,71,72],"Surgery Date","Age","BMI","Height","Weight","Smoking Status","Hormone Therapy","Chemotherapy","Radiotherapy","Postoperative Complications","Type of Reconstruction (Flap or Implant)","Timing of Reconstruction","Type of Mastectomy (Prophylactic or Therapeutic)","BRCA Mutation",[74,75,76],"Comparative","observational","retrospective",{"date":35,"type":36},{"date":79,"type":22},"2026-07-10",{"date":81,"type":22},"2026-08-20",{"name":42,"class":43},{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100642858","clinical-performance-and-multitasking-in-anesthesia--a-simulation-based-study-100642858","NCT07615582","Clinical Performance and Multitasking in Anesthesia : a Simulation-based Study","FOCUS","Inclusion Criteria:\n\n* Anesthesiology and intensive care resident or attending physician\n* Written informed consent\n\nExclusion Criteria:\n\n* None",true,{"count":92,"type":22},35,"Cognitive failure under multitasking conditions has been demonstrated in various settings, including healthcare. However, in anesthesiology, the impact of multitasking on clinical performance has not yet been fully characterized.\n\nThe objective of our study is to evaluate the impact of multitasking on anesthesiologists' clinical performance in a simulated setting.",[95,96,97,98,99,100],"Multitasking Behavior and Multitasking Ability","Clinical Performance","Simulation Training","Simulation Based Medical Education","Clinical Reasoning","Anesthesia","RECRUITING","2026-06-30",{"date":104,"type":36},"2026-07-02",{"date":106,"type":36},"2026-06-09",{"date":108,"type":22},"2026-12",{"name":42,"class":43},1,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":90,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":110},"100644858","validation-of-a-new-system-for-measuring-ventilation-and-co-production-100644858","NCT07677241","Validation of a New System for Measuring Ventilation and CO₂ Production","Comparison of a New Gas Exchange Measurement System During Exercise With a Reference System","PAIRFS","Inclusion Criteria:\n\n* Male or female adults (aged ≥ 18 years).\n* Individuals affiliated with, or benefiting from, a health insurance or social security scheme.\n* Individuals capable of understanding and signing an informed consent form.\n* Individuals fluent in French.\n\nExclusion Criteria:\n\n* Current tobacco smoking.\n* Any cardiovascular, respiratory, or musculoskeletal condition that could impair the ability to perform a maximal exercise test.\n* Individuals unwilling or unable to provide written informed consent.\n* Individuals with hierarchical, family, or close personal relationships with the principal investigator.",{"count":120,"type":22},20,"Gas exchange measurement systems are complex and require specialized facilities and expertise. As a result, access to these measurements remains limited, particularly in the field of sports performance. The aim of this validation study was to compare measurements obtained with a reference device and a new portable system.",[123],"Healhty",[125,126],"exercise","ventilatory measurement","2026-06-29",{"date":102,"type":36},{"date":130,"type":22},"2026-07-30",{"date":132,"type":22},"2026-10-30",{"name":42,"class":43},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":17,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":110},"100644047","acute-muscular-and-vascular-responses-to-a-single-session-of-exercise-with-bfr-in-copd-100644047","NCT07668921","Acute Muscular and Vascular Responses to a Single Session of Exercise With BFR in COPD","Blood Flow Restriction (BFR): a Novel Approach to Potentiate the Effects of Rehabilitative Exercise Training in COPD? Study of Acute - Muscular, and Vascular - Responses to a Single Session of Exercise With BFR","2BFREE_aigu","Inclusion Criteria:\n\n* Negative pregnancy test and use of an acceptable contraceptive method throughout the study duration for women of childbearing potential\n* Established COPD defined as obstructive ventilatory defect (FEV1\u002FFVC \\\u003C 0.70 or below the 5th percentile)\n* Resting lung hyperinflation defined as functional residual capacity \\> 2.5 z-scores according to the Global Lung Function Initiative (GLI)\n* Clinical stability of COPD for at least 3 months, with no recent exacerbation requiring treatment modification\n* Covered by a national health insurance system\n* Able and willing to provide written informed consent\n\nNon-inclusion Criteria:\n\n* Presence of a medical device incompatible with magnetic stimulation\n* Inability to perform an exercise test on a cycle ergometer\n* Any usual contraindication to exercise testing, including:\n\n  * Recent myocardial infarction (3-5 days)\n  * Unstable coronary insufficiency\n  * Severe stenotic valvular disease\n  * Uncontrolled arrhythmia with hemodynamic instability\n  * Recent unexplained syncope\n  * Uncontrolled heart failure\n  * Uncontrolled arterial hypertension (systolic blood pressure ≥200 mmHg and\u002For diastolic blood pressure ≥110 mmHg at rest)\n  * Acute thromboembolic disease and\u002For pulmonary edema\n* Conditions contraindicating the use of blood flow restriction (BFR), including:\n\n  * Coagulation disorder\n  * Peripheral neuropathy\n  * Uncontrolled hypertension (\\>160\u002F100 mmHg)\n  * Peripheral arterial disease\n  * History of venous thrombosis\n  * Intensive care unit stay within the last 3 months\n* Participation in another study during an exclusion period\n* Inability to be contacted in case of emergency\n* Individuals covered under Articles L1121-5 to L1121-8 of the French Public Health Code (protected populations, including pregnant or breastfeeding women, prisoners, minors, individuals under legal protection, psychiatric inpatients, etc.)\n* Staff members with a hierarchical relationship with the principal investigator","45 Years",{"count":144,"type":22},40,[25],"Exercise training is a cornerstone of pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD). However, some patients derive limited benefits from conventional exercise programs. Previous studies suggest that the magnitude of exercise-induced muscle fatigue is associated with training effectiveness, with patients unable to develop significant muscle fatigue (\"non-fatiguers\") showing smaller improvements in functional capacity and quality of life.\n\nBlood flow restriction (BFR) exercise consists in performing physical exercise while applying external pressure to the proximal part of the exercising limb, thereby reducing oxygen delivery to the muscles and limiting metabolite clearance. This approach has been shown to induce significant muscular adaptations despite the use of low exercise intensities. Because exercise intensity in COPD patients is often constrained by ventilatory limitations, BFR training may enhance muscle adaptations while reducing respiratory stress, potentially improving the effectiveness of PR.\n\nThe primary objective of this monocentric randomized crossover study is to compare lower-limb muscle fatigue induced by a single exercise session performed with BFR versus a standard exercise session in patients with COPD.",[148,149,150],"Control Condition","Pulmonary Disease (COPD), Chronic Obstructive","Blood Flow Restriction Training (BFRT)",[152,153,154,155,156],"Muscle Fatigue","COPD","Aerobic exercise","Resistance exercise","Blood Flow Restriction Training","2026-06-25",{"date":102,"type":36},{"date":160,"type":22},"2026-11",{"date":162,"type":22},"2028-12",{"name":42,"class":43},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100645038","one-year-prognostic-impact-of-microcirculation-assessed-by-nh-imr-angio-in-patients-hospitalized-for-acute-myocarditis-100645038","NCT07676201","One-year Prognostic Impact of Microcirculation Assessed by NH IMR Angio in Patients Hospitalized for Acute Myocarditis","MICROMYOC","Inclusion Criteria:\n\n* Male or female patients over the age of 18.\n* Patients hospitalized between June 2015 and July 2025.\n* Patients who presented with chest pain and at least 1 diagnostic criterion; or, in the absence of chest pain, at least 2 of the following diagnostic criteria:\n\n  * Electrocardiographic abnormalities (ST-segment elevation or depression, T-wave inversions, conduction disturbances such as type 3 atrioventricular block),\n  * Elevated troponin levels,\n  * Abnormal kinematics on echocardiography.\n* Associated with MRI findings of ≥2 tissue abnormalities (edema, hyperemia, myocardial fibrosis).\n* Coronary angiography performed during the initial hospitalization\n* Patient enrolled in or eligible for a social security program.\n* Patient who has expressed consent to participate.\n\nExclusion Criteria:\n\n* Absence of coronary artery disease confirmed by coronary angiography\n* Myocarditis secondary to immunotherapy\n* Presence of documented coronary artery disease (coronary angiography or cardiac CT)\n* Presence of cardiomyopathy (hypertrophic cardiomyopathy, dilated cardiomyopathy)\n* Infiltrative heart disease (sarcoidosis or cardiac amyloidosis)\n* Severe valvular heart disease\n* Takotsubo syndrome\n* Constrictive or chronic pericarditis\n* Loeffler's endocarditis\n* Left ventricular noncompaction\n* Cardiac tumor\n* Pulmonary embolism\n* Coronary spasm\n* Patients covered by Articles L1121-5 through L1121-8 of the Public Health Code (pregnant women, women in labor, and breastfeeding women; persons deprived of their liberty by judicial or administrative decision; adults under guardianship)",{"count":172,"type":22},106,"The goal of this observational study is to evaluate the association between post-coronary angiography IMR and medium-term clinical prognosis in patients with acute myocarditis. The main question it aims to answer is:\n\nIs there a correlation between impaired microcirculation and the occurrence of serious clinical events in this population of patients?",[175],"Myocarditis Acute",[177,178],"NH IMR","Coronary catheterization","2026-06-23",{"date":102,"type":36},{"date":182,"type":22},"2026-07-15",{"date":184,"type":22},"2026-10-15",{"name":42,"class":43},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":90,"sex":17,"minAge":18,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":110},"100644490","methodological-study-of-exercise-and-hypoxic-conditions-in-healthy-subjects-100644490","NCT07671638","Methodological Study of Exercise and Hypoxic Conditions in Healthy Subjects","ExHyp","Inclusion Criteria:\n\n* Healthy male or female volunteers\n* Aged 18-55\n* Body Mass Index \\\u003C30 kg\u002Fm²\n* Participants covered by a social security scheme\n* Participants capable of signing an informed consent form\n* Negative pregnancy test and highly effective contraception for women of childbearing age\n\nExclusion Criteria:\n\n* Cardiorespiratory, metabolic and neurological disorders, or other conditions assessed during the inclusion consultation that may affect physiological responses to exercise or hypoxia\n* Pharmacological treatment taken during the study, other than oral or implantable contraceptive medication for female volunteers of childbearing age","55 Years",{"count":195,"type":22},305,[25],"The aim of this protocol is to assess physiological responses during various physical exercise protocols (whole-body exercise such as cycling or treadmill running, or localised exercise such as knee extension) and during inhalation of a gas mixtures with various oxygen contents (similar to exposure at high altitude).",[199,200,201],"Healthy Subjects (HS)","Exercise","Hypoxia","2026-06-22",{"date":204,"type":36},"2026-06-26",{"date":206,"type":22},"2026-06-15",{"date":208,"type":22},"2031-12-31",{"name":42,"class":43},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":110},"100633716","treatment-failure-of-continuous-positive-airway-pressure-cpap-in-patients-with-obstructive-sleep-apnea-syndrome-osa-a-trial-comparing-polysomnography-and-the-sunrise-device-to-drive-treatment-adjustment-decisions-100633716","NCT07530302","Treatment Failure of Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea Syndrome (OSA): A Trial Comparing Polysomnography and the Sunrise Device to Drive Treatment-Adjustment Decisions.","Treatment Failure of Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea Syndrome (OSA): A Randomized Controlled Trial Comparing Polysomnography and the Sunrise Device to Drive Treatment-Adjustment Decisions.","SUNCPAP","Inclusion Criteria:\n\n* Adults aged 18 to 85 years\n* Patients treated with Resmed CPAP\n* Residual apnea-hypopnea index under CPAP (rAHI(CPAP) \\> 10 events\u002Fhour)\n* Access to a smartphone and home internet connection, and ability to use a mobile application\n* Signed informed consent\n* Affiliated with, or beneficiary of, a national health insurance program\n\nExclusion Criteria:\n\n* Severe chronic obstructive or restrictive pulmonary disease, with or without supplemental oxygen\n* Unstable cardiovascular disease or severe heart failure requiring hospitalization within the past 3 months, or meeting New York Heart Association (NYHA) class III or IV criteria\n* Conditions affecting mandibular condyle rotation or temporomandibular joint function\n* Refusal to shave excessive facial hair when required for proper placement of the Sunrise device\n* Participation in another interventional clinical study or currently within an exclusion period of another study\n* Individuals who, in the investigator's judgment, are unlikely to comply with study procedures or requirements\n* Individuals who cannot be contacted in case of emergency\n* Persons protected under French Public Health Code articles L1121-5, L1121-6, and L1121-8 (including pregnant or breastfeeding women, persons deprived of liberty, individuals under psychiatric care under articles L.3212-1 or L.3213-1, individuals admitted to healthcare or social institutions for reasons other than research, and persons under legal protection or unable to provide informed consent)\n* Staff members with a hierarchical relationship to the principal investigator","85 Years",{"count":220,"type":22},105,[25],"The goal of this clinical trial is to determine whether treatment-adjustment decisions based on one night of home monitoring with the Sunrise device are comparable to decisions based on one night of in-laboratory polysomnography (PSG) in adults with obstructive sleep apnea (OSA) who remain insufficiently controlled with continuous positive airway pressure (CPAP) therapy.\n\nThe main questions it aims to answer are:\n\n* Do Sunrise-based assessments lead to similar therapeutic decisions as PSG-based assessments?\n* Are residual apnea-hypopnea indices measured by Sunrise comparable to those measured by PSG?\n\nParticipants will complete both assessment sequences in a randomized cross-over design. They will:\n\n* Use the Sunrise device for several nights with and without CPAP.\n* Undergo one night of PSG with and without CPAP.\n* Have their CPAP therapy reviewed based on the results of each assessment method.",[224],"Sleep Apnea Syndrome, Obstructive",[226,227,228,229],"Obstructive sleep apnea","Randomized","Cross-over","CPAP",{"date":231,"type":36},"2026-06-17",{"date":233,"type":36},"2026-06-10",{"date":235,"type":22},"2029-09",{"name":42,"class":43},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100642401","vertebral-augmentation-and-percutaneous-fixation-for-thoracolumbar-burst-fractures-requiring-corpectomy-100642401","NCT07645092","Vertebral Augmentation and Percutaneous Fixation for Thoracolumbar Burst Fractures Requiring Corpectomy","EXVERCOR","Inclusion Criteria:\n\n* Adult patient at the time of the fracture.\n* Patient who underwent posterior fixation (+1\u002F-1 levels) combined with anterior vertebral augmentation:\n\nFracture with a Load Sharing Classification (LSC) score ≥ 7 Single vertebral level involved Percutaneous surgery\n\n* Preoperative CT scans (thoracic and lumbar spine)\n* Postoperative CT scans (thoracic and lumbar spine)\n\nExclusion Criteria:\n\n* Persons deprived of liberty by judicial or administrative decision, or persons under legal protection measures.\n* Non-inclusion criteria include:\n\nPerformance of a laminectomy Pathological fractures Fractures classified as type C or B2 according to the AO Spine classification Presence of severe scoliosis Neurological deficit More than one vertebral fracture","100 Years",{"count":246,"type":22},30,"This study evaluates minimally invasive vertebral augmentation combined with percutaneous fixation for the treatment of severe thoracolumbar burst fractures. Traditionally, fractures with a Load Sharing Classification (LSC) score ≥7 require corpectomy, which is associated with significant morbidity. Newer techniques, such as vertebral expansion devices, may restore vertebral height and alignment while reducing the need for invasive anterior procedures. This study aims to assess their effectiveness in this population.",[249],"Thoracolumbar Burst Fractures","2026-06-08",{"date":252,"type":36},"2026-06-12",{"date":206,"type":22},{"date":255,"type":22},"2027-06-15",{"name":42,"class":43},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":110},"100642452","characterization-of-the-involvement-of-the-subthalamic-nucleus-during-wakefulness-and-sleep-in-parkinsons-disease-contribution-of-deep-brain-stimulation-100642452","NCT07637955","Characterization of the Involvement of the Subthalamic Nucleus During Wakefulness and Sleep in Parkinson's Disease: Contribution of Deep Brain Stimulation","SLEEP-STN","Inclusion Criteria:\n\n* Adult patients with Parkinson's disease, followed at Grenoble University Hospital, for whom surgery to implant deep brain stimulation electrodes in the subthalamic nucleus is indicated\n* Patients agreeing to be implanted with a Medtronic PERCEPT stimulator (routine care)\n* Patients who have given and signed informed consent\n* Patients covered by social security or a similar scheme\n\nExclusion Criteria:\n\n* Individuals who do not understand\u002Fspeak French (prevents completion of questionnaires)\n* Any condition that, in the investigator's opinion, will prevent the participant from successfully or safely completing the study procedures (i.e., dementia, severe depression, etc.)\n* Subjects on exclusion from another study\n* Protected persons (Articles L1121-5 to L1121-8 of the French Public Health Code)",{"count":265,"type":22},15,[25],"Sleep-wake disturbances are common in Parkinson's disease. These disturbances are associated with a decline in patients' quality of life and a poor prognosis. This clinical research project follows a study conducted in non-human primates that began in 2017 at the Grenoble Institute of Neuroscience. In this study, the investigators confirmed the existence of sleep-wake behavior disturbances in the macaque model of the disease, and the investigators characterized their nature and expression. These disturbances were founded to be very similar to those observed in patients with Parkinson's disease. The investigators then explored the involvement of different brain structures, potentially targets for deep brain stimulation, in sleep-wake behavior under healthy conditions and dopamine depletion (Parkinson's disease model). Among the deep brain stimulation targets being explored, the subthalamic nucleus (STN), still under investigation in this preclinical program, is a promising candidate for deep brain stimulation because this nucleus is strongly implicated in motor behavior and, more recently, in sleep\u002Fwake behavior. An ongoing study in non-human primates shows that it is possible to identify states of alertness based on STN activity, and an automatic detection algorithm is currently being evaluated.\n\nFurthermore, this study will allow for the characterization of sleep\u002Fwake behavioral disturbances (diurnal and nocturnal) in patients with Parkinson's disease. Finally, this study will enable a correlation analysis between disease severity and sleep\u002Fwake disturbances.",[269],"Parkinson Disease",[271,272,273],"Parkinson's disease (PD)","Subthalamic nucleus (STN)","Sleep-wake disturbances","2026-06-04",{"date":233,"type":36},{"date":277,"type":22},"2026-07",{"date":279,"type":22},"2029-07",{"name":42,"class":43},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":290,"conditions":291,"keywords":301,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":110},"100619680","study-of-the-serotype-and-genotype-of-bk-virus-in-kidney-transplant-recipients-and-their-donors-to-identify-individuals-at-risk-of-nephropathy-100619680","NCT07347769","Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy","TYPIK","Inclusion Criteria:\n\n* Kidney transplant patients with a first positive BK virus viral load in urine. - BK virus viral load in urine \\> 3 log copies\u002FmL.\n* More than 3 months post-transplant and less than 2 years post-transplant.\n* Men or women aged 18 years and older.\n* Followed up at Grenoble Alpes University Hospital.\n* Affiliated with social security or beneficiary of such a scheme.\n* Patients who are not opposed to the TYPIK study.\n\nExclusion Criteria:\n\n* Expected renal graft survival is \\\u003C 6 months, estimated by an eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m² at the time of BKPyV viruria\n* Patients who object to the use of their data and\u002For samples for research purposes\n* Subjects who are excluded from another study\n* Subjects under administrative or judicial supervision",{"count":289,"type":22},100,"The aim of this observational study is to characterize the urinary replication of BK polyomavirus (BKV) in kidney transplant recipients. Although BKV reactivation after transplantation is well established, the origin of the replicating virus remains uncertain. Current evidence suggests that BKV detected in recipients may originate either from the transplanted kidney (donor-derived) or from viral reactivation in the recipient. The evaluation of new biomarkers to predict BKV replication are needed.\n\nThis study seeks to address the following key questions:\n\n* Origin of the replicating virus: Is the BKV detected in the recipient identical to the virus originating from the donor kidney?\n* Host immune response and viral genotype: Is there an association between the recipient's immune response and the genotype of the replicating BKV?\n* Differences in immune response according to viral replication profile: Does the immune response differ between patients presenting isolated BKV viruria and those with both viruria and viremia?\n* Can new biomarkers help predict BKV replication and viremia?\n\nPatients will be grouped according to their BKV replication profile:\n\nGroup 1: patients with BKV viruria without viremia Group 2: patients with both BKV viruria and viremia Comparisons between these two groups will help identify whether different viral genotypes or immune responses are associated with systemic dissemination (viremia).\n\nKidney transplant recipients will be included if they present BKV viruria during their post-transplant follow-up. Additional blood samples will be collected during scheduled follow-up visits at the university hospital. These visits are part of routine clinical care, and no extra visits will be required specifically for the study.",[292,293,294,295,296,297,298,299,300],"Nephropathy","Opportunistic Viral Infection","Polyoma Virus Nephropathy","BK Nephropathy","BK Viremia; BKV DNAemia","BK Virus Infection","BK Polyomavirus","Immune Response","Neutralizing Antibodies",[302,303,304,305,306,307,308],"TTV","BK polyomavirus","neutralizing antibodies","ELISPOT BKV","genotype","miRNA BKV","urinary chimiokine","2026-05-22",{"date":311,"type":36},"2026-05-27",{"date":313,"type":36},"2026-03-11",{"date":315,"type":22},"2030-09-11",{"name":42,"class":43},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":90,"sex":17,"minAge":324,"maxAge":325,"enrollmentInfo":326,"targetDuration":328,"studyType":56,"phases":4,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":110},"100621227","the-monument-test--a-new-tool-for-assessing-the-ability-to-name-and-identify-unique-entities-tedimo-100621227","NCT07367880","The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)","TeDIMO","Inclusion criteria :\n\n* Alzheimer's disease:\n\n  * Age ≥ 50 years and older\n  * Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011.\n  * Score 18≤ MMSE ≤26\n* Controls:\n\n  * Age ≥ 50 years and older\n  * MMSE score ≥ 26 For all subjects\n  * No objection from the participant\n\nExclusion criteria\n\n* Alzheimer's disease:\n\n  * Persons referred to in Articles L1121-5 to L1121-8 of the CSP\n* Controls:\n\n  * Memory complaints\n  * Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects\n  * Significant neurological or psychiatric history\n  * Taking psychotropic medication (neuroleptics)\n  * Poor command of the French language, comprehension difficulties\n  * Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.)\n  * Insufficient exposure to the media and\u002For socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)","50 Years","95 Years",{"count":327,"type":22},220,"1 Month","The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments.",[331],"Alzheimer s Disease",[333,334,335,336],"unique entities","denomination","identification","landmarks",{"date":338,"type":36},"2026-05-26",{"date":340,"type":36},"2026-02-23",{"date":342,"type":22},"2032-02-01",{"name":42,"class":43},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":17,"minAge":351,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":353,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":21},"100568925","role-of-actg2-variants-in-smooth-muscle-determination-and-function-in-pediatric-intestinal-pseudo-obstruction-100568925","NCT06687564","Role of ACTG2 Variants in Smooth Muscle Determination and Function in Pediatric Intestinal Pseudo-obstruction.","SMOOTH-PIPO","Inclusion Criteria:\n\nPIPO Population:\n\n1. Minor or adult patient ≥ 4 years of age\n2. Patient with PIPO before age 18\n3. Male or female\n4. Patient with PIPO meeting at least 2 of the ESPGHAN criteria (Thapar et al 2018) and carrying the R178, R257, R40 or A136 mutation of the ACTG2 gene.\n5. Patient whose assent has been obtained and whose legal guardians have given their written informed consent\n6. Patient affiliated to the French Social Security system or benefiting from an equivalent plan\n\nWT population:\n\n\\- iPS cell lines MS573 or WT8288 or 202CT or SD378M, from the Nantes University Hospital biological collection and generated from samples from control patients without POIC who have consented to donate their samples.\n\nExclusion Criteria:\n\nPIPO population :\n\n1. Patients with a history of radiotherapy treatment\n2. Patient with lymphocyte lineage damage","4 Years",{"count":44,"type":22},[25],"The primary objective of this study is to describe the transcriptional impact of R178, R257, R40 or A136 variants of the ACTG2 gene on iPS differentiation mechanisms up to organoids derived from PIPO patient samples versus those derived from control \u002F WT patients (generation of IPS from cultured cell lines), at different stages of their experimental ex vivo development.",[356],"PIPO",[356,358,359,360,361,362,363,364],"CIPO","ACTG2","pseudo-obstruction","organoid","iPS","Pediatric Intestinal Pseudo-Obstruction","Chronic Intestinal Pseudo-obstruction",{"date":311,"type":36},{"date":367,"type":36},"2026-02-04",{"date":369,"type":22},"2032-02-03",{"name":42,"class":43},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":388,"locationsCount":110},"100626899","qualitative-exploration-of-key-symptoms-of-stricturing-crohns-disease-toward-the-development-of-a-clinical-assessment-score-100626899","NCT07441629","Qualitative Exploration of Key Symptoms of Stricturing Crohn's Disease: Toward the Development of a Clinical Assessment Score.","SYMCROHNS","Inclusion Criteria:\n\n* Adult patient (≥ 18 years old).\n* With a confirmed diagnosis of Crohn's disease.\n* Presenting a stricturing form of the disease (confirmed clinically, endoscopically, radiologically, or surgically).\n* Followed in a hospital department managing inflammatory bowel diseases (IBD).\n* Clinically stable at the time of the interview (not experiencing an acute episode requiring urgent hospitalization).\n* Able to understand and speak French, in order to participate in a qualitative interview.\n\nExclusion Criteria:\n\n* Current hospitalization for a severe Crohn's disease flare, acute intestinal obstruction, or any situation requiring urgent medical care.\n* Severe cognitive impairment, communication deficits, or acute psychiatric disorder preventing understanding of the interview or reliable expression of experiences.\n* Major uncontrolled medical comorbidity (e.g., active cancer under treatment, severe heart failure) making the interview inappropriate or likely to confound symptom interpretation.\n* Technical inability to participate in an interview (no access to the proposed modalities: unable to travel, no access to videoconference if a remote interview is required).\n* Pregnant women\n* Persons deprived of their liberty\n* Persons receiving psychiatric care\n* Persons admitted to a healthcare or social institution\n* Adults subject to a legal protection measure\n* Persons unable to express their consent",{"count":265,"type":22},"The goal of this qualitative study is to identify and better understand the symptoms of stricturing Crohn's disease in order to inform the development of more appropriate clinical evaluation scores. This study focuses on adult patients diagnosed with stricturing Crohn's disease who are followed in hospital gastroenterology departments.\n\nThe main questions it aims to answer are:\n\n* Which symptoms are perceived by patients as the most specific and significant features of stenosing Crohn's disease?\n* Which symptoms are perceived by patients as early warning signs of a stenosing flare?\n* How does stenosing Crohn's disease impact daily life, mental health, and quality of life, and what coping strategies do patients use to manage symptoms and limit their impact?\n\nParticipants will:\n\n* Take part in a one-hour individual semi-structured interview, conducted in person (at the hospital, at home, or in another agreed location) or by videoconference\n* Have the interview audio-recorded for transcription and qualitative analysis\n* Be offered the opportunity to review and validate the transcript and summary of their interview before final anonymized analysis",[381],"Crohn Disease (CD)","2026-05-18",{"date":384,"type":36},"2026-05-20",{"date":386,"type":22},"2026-05",{"date":160,"type":22},{"name":42,"class":43},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":110},"100588705","metabolic-reprogramming-of-monocytes-in-inflammatory-flares-of-inflammatory-bowel-diseases-100588705","NCT06944873","Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases","REPRO-MICI","Inclusion Criteria:\n\n* Men and women over 18\n* Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up\n* Patient not objecting to the REPRO-MICI study\n\nExclusion Criteria:\n\n* Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).\n* Patients with positive HIV, HBV or HCV serology.\n* Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.",{"count":246,"type":22},"Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.",[399],"Inflammatory Bowel Disease (IBD)",[401,402],"Monocytes","Metabolic reprogramming",{"date":404,"type":36},"2026-05-19",{"date":406,"type":22},"2026-07-01",{"date":408,"type":22},"2028-07-31",{"name":42,"class":43},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":110},"100525304","screening-for-advanced-liver-fibrosis-using-non-invasive-tests-in-primary-care-100525304","NCT06119997","Screening for Advanced Liver Fibrosis Using Non-invasive Tests in Primary Care","ANTICIP-SP","Inclusion Criteria:\n\n* Patients between 18 and 70 years of age\n* FIB-4 2.67\n* Patients covered by Health Insurance System\n\nExclusion Criteria:\n\n* Prescription triggering FIB-4 emanate from a hepatogastroenterologist or oncologist\n* Conditions associated with high risk false-positive FIB-4: ASAT or ALAT \\> 300 IU\u002FL, platelets \\\u003C50 G\u002FL or \\>500 G\u002FL.\n* Patient refusing to participate\n* Subjects under guardianship or deprived of liberty","70 Years",{"count":419,"type":22},500,"Liver fibrosis screening is possible at the asymptomatic stage through a healthcare management strategy currently recommended for patients with risk factors for chronic liver disease. It is based on a sequential strategy involving a 1st-line test, fibrosis score calculation (FIB-4).\n\nGiven this opportunity to identify advanced fibrosis in asymptomatic patients, the project aims to set up this screening program in the Grenoble area with Biogroup Laboratories, in collaboration with the Hepato-gastroenterology department (HGE) of Grenoble University Hospital. The aim of this study is to evaluate the success of sequential screening using FIB-4, followed by a specialized fibrosis test for the diagnosis of advanced hepatic fibrosis",[422],"Hepatic Fibrosis",{"date":384,"type":36},{"date":425,"type":36},"2025-06-26",{"date":427,"type":22},"2028-07-30",{"name":42,"class":43},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":439,"conditions":440,"keywords":443,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":110},"100442205","tumor-immune-microenvironment-involvement-in-colorectal-cancer-chemoresistance-mechanisms-100442205","NCT05038358","Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms","Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms: a Patient-derived Tumoroids Prospective Collection From Systemic Treatment Naive Tumors","CRC-ORGA2","Inclusion Criteria:\n\n* Male and female over 18 years old.\n* Managed at the CHUGA for a colorectal adenocarcinoma\n* With an indication for immediate surgical resection as part of the care.\n* Patient naive from neo-adjuvant chemotherapy\n* Patient did not object to the CRC-ORGA-2 study\n\nExclusion Criteria:\n\n* Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress).\n* Patients with positive HIV, HBV, HCV serology.",{"count":438,"type":22},60,"Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that early development of chemoresistance mechanisms remains a major challenge. In order to better characterize these mechanisms, the aim is to develop a model of tumoroids derived from patients with a colorectal tumors prior to any systemic anti cancer treatment. This project will both allow us to study the role of the immunological microenvironment in chemoresistance and identify new predictive markers of tumor response. It will then serve to develop innovative personalized medicine strategies by targeting the newly identified mechanisms. This study should in fine help to improve the cancer patient's care.",[441,442],"Primary Tumor","Colon Tumor",[444],"Organoid collection from fresh human primary colonic tumor tissue",{"date":404,"type":36},{"date":447,"type":36},"2022-12-12",{"date":449,"type":22},"2030-12-31",{"name":42,"class":43},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":472,"leadSponsor":474,"locationsCount":4},"100640455","clinical-utility-of-libs-multi-element-imaging-and-the-iff-algorithm-in-chronic-lung-diseases-100640455","NCT07597187","Clinical Utility of LIBS Multi-Element Imaging and the IFF Algorithm in Chronic Lung Diseases","Evaluation of the Clinical Utility of LIBS Multi-Element Imaging and the IFF Algorithm for the Etiological and Medico-Legal Management of Chronic Lung Diseases","PNEUMO-LIBS","Inclusion Criteria:\n\n* Adult patient aged 18 years or older.\n* Diagnosis or documented clinical suspicion of chronic lung disease, including interstitial lung disease, pulmonary granulomatosis such as sarcoidosis, or pulmonary emphysema.\n* Availability of a lung tissue biopsy sample obtained during routine medical care and stored as a formalin-fixed paraffin-embedded sample.\n* Sufficient medical record information to document the clinical context, occupational or environmental exposure history, smoking status, imaging, pathology reports, and other relevant routine-care data.\n* No documented objection to the secondary use of health data and biological samples for this research.\n\nExclusion Criteria:\n\n* Documented objection to participation in the study or to the secondary use of health data or biological samples for research.\n* Missing, unavailable, degraded, or technically unusable biopsy sample.\n* Insufficient medical record information to document the clinical context or exposure history.\n* Lung condition outside the scope of the study, such as isolated acute infection, isolated cardiac disease, or primary lung cancer.\n* Patient under legal protection when the applicable legal conditions for non-opposition cannot be fulfilled.",{"count":460,"type":22},70,"PNEUMO-LIBS is a multicenter, non-interventional observational study designed to evaluate whether multi-element tissue imaging by Laser-Induced Breakdown Spectroscopy (LIBS), combined with an artificial intelligence-based analysis tool called Interesting Features Finder (IFF), may help physicians better understand the possible causes of chronic lung diseases.\n\nThe study focuses on adult patients with chronic lung diseases for which a lung biopsy has already been performed as part of routine medical care. These diseases include diffuse interstitial lung diseases, pulmonary granulomatoses such as sarcoidosis, and emphysema, especially when an environmental or occupational exposure is suspected but not clearly demonstrated.\n\nSome chronic lung diseases may be influenced by inhaled mineral or metallic particles, such as silica, aluminum, titanium, or other metals. However, these exposures are often difficult to document at the individual patient level. Standard clinical, radiological, and pathological investigations do not usually provide direct information on the presence and distribution of such elements within lung tissue.\n\nLIBS is an imaging technique that can detect and map chemical elements directly in tissue samples, including archived formalin-fixed paraffin-embedded biopsy blocks. In this study, lung biopsy samples will be analyzed with LIBS to search for elemental signatures that may be compatible with occupational or environmental exposures. The IFF algorithm will then be used to help interpret the LIBS data and identify rare or unexpected elemental signals.\n\nThe study does not require any additional biopsy, blood test, imaging examination, treatment, or hospital visit for participants. It uses tissue samples and medical data already collected during routine care. The results of LIBS and IFF analyses will be presented to the treating physician or investigator, who will complete standardized online questionnaires at three time points: before receiving the LIBS results, after receiving the LIBS report, and after receiving the IFF-assisted interpretation.\n\nThe main objective is to assess the perceived clinical utility of LIBS imaging for physicians, particularly regarding etiological understanding, possible occupational disease recognition, and prevention-oriented reasoning. Secondary objectives include assessing the added value of the IFF algorithm and evaluating the feasibility of a centralized multicenter workflow for sample transfer, LIBS analysis, IFF processing, result reporting, and questionnaire completion.\n\nThe study aims to include approximately 70 patients across several French hospital centers. Its results may support the development of future diagnostic, occupational health, and environmental medicine approaches, without modifying the medical care of participants during the study.",[463,464,465,466,467,468],"Interstitial Lung Diseases (ILD)","Pulmonary Emphysema","Chronic Lung Diseases","Occupational Lung Diseases","Environmental Exposure","Occupational Exposure","2026-05-12",{"date":404,"type":36},{"date":406,"type":22},{"date":473,"type":22},"2027-07-01",{"name":42,"class":43},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":483,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":501},"100622788","functional-impact-of-acute-respiratory-viral-infections-in-older-adults-100622788","NCT07388173","Functional Impact of Acute Respiratory Viral Infections in Older Adults","Assessment of Functional Impact of Acute Respiratory Viral Infections in Older Adults - An International Multi-center Study","AFIRI","Inclusion Criteria:\n\n* Male or female subjects aged 60 years or older\n* Hospitalized in a study center (emergency department, infectious disease, internal medicine or geriatric hospital wards…) for acute respiratory infection (refer to table 1 below for definition).\n* Confirmed positive PCR test for influenza, SARS-CoV-2, RSV, or human metapneumovirus (hMPV). Participants with co-infections with other viral or bacterial agents can be included.\n\nExclusion Criteria:\n\n* Participants with conditions significantly impacting short-term functional status, such as severe disability (ADL score ≤2 or Clinical Frailty Scale ≥7), terminal illness, palliative care needs, or inability to comprehend and complete study questionnaires due to severe stroke sequelae, complete sensory loss, advanced dementia, or similar impairments.\n* Participants that refuse or are unable to answer the 3- and 6-months follow-up phone call assessments\n* Positive laboratory test for single (mono-infection) virus other than influenza, SARS-CoV-2, RSV, or human metapneumovirus (HMPV)\n* Participant in exclusion period for another study using an investigational \u002F unapproved medicinal product.\n* Participant referred to in articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons : pregnant woman, parturient, breastfeeding mother, person deprived of liberty by judicial or administrative decision, persons undergoing psychiatric care under articles L.3212-1 and L.3213-1 who do not fall under article L.1121-8, persons admitted to a healthcare or social institution for purposes other than research, minors, person under legal protection or unable to express consent).\n* Individuals opposed to participating in the research\n* Staff members with a hierarchical relationship to the principal investigator","60 Years",{"count":485,"type":22},1600,"The prevention of infectious diseases in older adults remains a major public health challenge, as acute respiratory infections are a leading cause of hospitalisation, mortality, and functional decline worldwide. Immunosenescence and environmental exposures increase susceptibility to infection and reduce vaccine effectiveness in this population. Respiratory viruses, including influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus, account for a substantial share of this burden, much of which is vaccine-preventable. However, their impact on functional decline and recovery in older adults remains insufficiently characterized. This international study aims to assess the effect of hospitalization for major respiratory viral infections on loss of autonomy in individuals aged 60 years and older, to inform targeted prevention and vaccination strategies.",[488],"Respiratory Infections in Old Age",[490,491,492],"functional dependency","respiratory infection","elderly people","2026-05-07",{"date":495,"type":36},"2026-05-08",{"date":497,"type":36},"2026-01-15",{"date":499,"type":22},"2028-06-15",{"name":42,"class":43},24,{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":510,"targetDuration":512,"studyType":56,"phases":4,"briefSummary":513,"conditions":514,"keywords":517,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":110},"100640922","coronary-artery-disease-screening-in-patients-with-chronic-kidney-disease-100640922","NCT07585695","Coronary Artery Disease Screening in Patients With Chronic Kidney Disease","Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease","EVACKD","Inclusion Criteria:\n\n* Male or female patients aged over 18 years\n* Affiliated with the French social security system\n* Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR \\\u003C 30 mL\u002Fmin\u002F1.73 m², or GFR \\\u003C 45 mL\u002Fmin\u002F1.73 m² with albuminuria \\> 30 mg\u002Fg, or GFR \\\u003C 60 mL\u002Fmin\u002F1.73 m² with albuminuria \\> 300 mg\u002Fg)\n* Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment\n* Having expressed no objection to participation in this study\n\nExclusion Criteria:\n\n* Legally protected adult (Article L1121-8 of the French Public Health Code)\n* Person deprived of liberty (Article L1121-8 of the French Public Health Code)\n* Pregnant woman\n* Patient who has undergone a normal coronary exploration within the past year",{"count":511,"type":22},283,"25 Months","Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.",[515,516],"Chronic Kidney Disease (CKD)","Coronary Artery Disease (CAD)",[518,519,520],"Chronic Kidney Disease","Coronary Flow Reserve","coronary artery disease","2026-05-06",{"date":523,"type":36},"2026-05-14",{"date":525,"type":22},"2026-06-01",{"date":527,"type":22},"2028-01-31",{"name":42,"class":43},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":543,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":110},"100635999","pre-operative-interventional-paramedical-consultation-what-about-the-implantable-device-100635999","NCT07559981","Pre-operative Interventional Paramedical Consultation: What About the Implantable Device?","COPAIN","Inclusion Criteria:\n\n* Patients scheduled to have an implantable port fitted in the Radiology Department at CHUGA\n* Patients aged 18 or over\n\nExclusion Criteria:\n\n* Patients with a history of implantable port placement\n* Implantable port placement for a non-oncological indication\n* Emergency implantable port placement that could increase the patient's anxiety (port placement scheduled as an emergency within 7 days of the oncology consultation)\n* Subject currently excluded from another study\n* Persons referred to in Articles L1121-5 to L1121-8 of the Public Health Code (i.e. all protected persons: pregnant women, women in labour, breastfeeding mothers, persons deprived of their liberty by judicial or administrative order, and persons subject to a legal protection measure)",{"count":537,"type":22},150,[25],"The placement of implantable ports is carried out at CHUGA by several departments, including the Interventional Radiology Department.\n\nThe radiology team places between 350 and 370 implantable ports each year (figures for 2023: 361, 2024: 363).\n\nIt is a short procedure (less than an hour), carried out under local anaesthetic. Following this, the interventional radiologist makes two incisions: one at the base of the neck and the second beneath the collarbone on the same side. The olive-sized housing is positioned at the incision near the collarbone. The catheter is connected to the device and then enters the neck vein at the second incision after travelling under the skin. The two incisions are closed with a few stitches, still under local anaesthetic. After the procedure, the patient gets dressed and can go home with a prescription for nursing care. Due to a lack of available medical time, there is currently no pre-procedural consultation carried out by radiologists prior to this procedure. The information is therefore provided by the oncologist during the oncology consultation, alongside a wealth of other information regarding the oncological condition. When an appointment is made through the interventional radiology department's reception, a standardised written information sheet is sent to the patient along with the appointment letters. The MERM team in the interventional radiology department observed that information regarding the procedure's conduct almost invariably had to be repeated when the patient was admitted to the procedure suite. According to an internal department assessment conducted over one month, the investigators found that of 31 patients attending for the insertion of an implantable port, 11 patients (35.5%) were highly anxious, 9 patients (29%) had received no information at all regarding the procedure, and only 8 patients (25.8%) were not anxious and felt they had been properly informed. Furthermore, 4 patients (12.9%) did not undergo the procedure due to a major error in the management of anticoagulants, and 7 patients (22.5%) had not undergone the preoperative blood tests normally recommended.\n\nDuring the pre-procedure consultation, which lasts approximately 30 minutes, you will be given full details of the examination process, from settling in the procedure room right through to the dressing. Pre- and post-operative instructions will also be provided, along with the relevant prescriptions (discontinuation of anticoagulants, Betadine shower, referral for a blood test to be carried out in the laboratory beforehand, dressings and a follow-up visit from a private nurse afterwards). The issue of transport to and from the hospital on the day of the procedure (arrangements, transport vouchers) will also be discussed. This time will be used to introduce the patient to the department and the healthcare staff who will be looking after them, using visual aids (photographs), as well as to show them a device identical to the one that will be implanted, if they wish.\n\nUnlike the information currently provided on the day of the examination, this consultation will take place in a confidential and calm setting where the patient will also be able to ask any questions they may have.\n\nAssessing patients' anxiety preoperatively is not easy, but the most widely validated scale is the State and Trait Anxiety Index (STAI) (1), which has been translated into French but comprises 20 items and is therefore cumbersome to administer.\n\nThe Visual Analogue Scale (VAS) is much easier to use in practice and began to be used in the context of anxiety in the 1970s (2) A prospective study (3) conducted at Poitiers University Hospital demonstrated a good correlation between the STAI scale and the Visual Analogue Scale (VAS) upon entering the operating theatre. A randomised study of 89 patients conducted at Limoges University Hospital showed that an information consultation held approximately 7 days before gastrointestinal surgery reduced patients' anxiety as assessed by the VAS-Anxiety (VAS-A) score (4).\n\nThe investigators therefore hypothesise that an information consultation conducted by a MERM would help to reduce anxiety in patients coming to our department for the placement of an implantable port in an oncological context",[541,542],"Anxiety","Paramedical Consultation",[544,545,546,547],"implantable chamber","Medical Radiology Technician","paramedical consultation","patient's anxiety","2026-05-04",{"date":495,"type":36},{"date":551,"type":22},"2026-09",{"date":553,"type":22},"2029-11",{"name":42,"class":43},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":563,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":110},"100563041","phase-1-evaluation-of-the-safety-of-lipiodol-embolization-in-symptomatic-digital-osteoarthritis-refractory-to-conventional-treatment-100563041","NCT06611007","Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment","Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment: a Pilot Study of 15 Patients","EMBARDI","Inclusion Criteria:\n\n* Patients aged ≥ 40 years.\n* Osteoarthritis of the hand according to American College of Rheumatology criteria 1990\n* Osteoarthritis affecting at least two proximal and\u002For distal interphalangeal joints with a radiological Kellgren-Lawrence stage ≥ 2.\n* Symptomatic osteoarthritis within the last 3 months.\n* Visual analogue pain scale of the hand to be treated ≥ 40\u002F100 mm (most painful hand).\n* Inadequate response, adverse effects and\u002For contraindication to NSAIDs and non-opioid analgesics.\n* Patient affiliated to french social security or a similar health assurance.\n\nExclusion Criteria:\n\n* History of allergy to iodinated contrast media, LipiodolⓇ or poppies.\n* Vasomotor disorders (Raynaud\\'s syndrome, scleroderma, acrocyanosis).\n* Stenosis (\\>50%) or known atheromatous arterial occlusion of the upper limbs.\n* Obliterative arterial disease of the lower limbs at the critical ischaemia stage.\n* Severe to end-stage chronic renal insufficiency (glomerular filtration rate \\< 30ml\u002Fmin\u002F1.73m2), dialysis or renal transplant.\n* Arteritis such as thromboangiitis obliterans disease or other diseases\n* Previous thrombosis\u002Fdissection of the radial artery.\n* Chronic inflammatory rheumatic disease (rheumatoid arthritis, psoriatic arthritis, microcrystalline arthritis, etc.).\n* Known hyperthyroidism or large multinodular goiter.\n* Traumatic lesions, haemorrhages or chronic bleeding in the hand (not completely resolved within 3 months of the start of the lesion) requiring embolisation.\n* Pregnant or breast-feeding.\n* Patients covered by articles L1121-5 to L1121-8 of the French Public Health Code and\u002For who do not speak French.\n* Patients in a period of exclusion or in the course of another interventional clinical trial.","40 Years",{"count":265,"type":22},[566,567],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate the safety of arterial embolization using Lipiodol® in patients with symptomatic hand osteoarthritis refractory to conventional treatment. It will also learn about the efficacy of arterial embolization with Lipiodol® in reducing pain and improving hand function.\n\nThe main questions it aims to answer are:\n\n* What are the side effects and complications associated with the Lipiodol® arterial embolization procedure?\n* Does arterial embolization reduce pain intensity and improve hand function?\n\nResearchers will evaluate patients over a 6-month period to assess the safety of Lipiodol® embolization and its impact on joint pain, swelling, and functional capacity. Participants will:\n\n* Undergo arterial embolization with Lipiodol®\n* Participate in regular follow-ups to monitor pain relief, hand function, and any side effects\n* Have imaging studies to assess changes in joint vascularisation and damage",[570],"Osteoarthritis",[572,573,574],"Therapeutic embolization","Safety","Hand osteoarthritis",{"date":576,"type":36},"2026-05-05",{"date":578,"type":36},"2025-01-30",{"date":580,"type":22},"2028-07-15",{"name":42,"class":43},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":90,"sex":17,"minAge":483,"maxAge":589,"enrollmentInfo":590,"targetDuration":4,"studyType":23,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":110},"100442999","effect-of-hypoxic-conditioning-on-cerebrovascular-health-in-the-elderly-100442999","NCT05048680","Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly","HYPOXAGE","Inclusion Criteria:\n\n* 60 to 80 years of age;\n* Being physically inactive (less than 150 min\u002Fweek of moderate to intense physical activity);\n* No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program;\n* Health coverage;\n* Being able to provide written fully informed consent.\n\nExclusion Criteria:\n\n* Body-mass index \\>30 kg\u002Fm2;\n* Smoking (\\> cigarettes\u002Fday);\n* Alcohol use (\\> 10g\u002Fday);\n* Mental disorder or history of mental disorder;\n* Beta-blockade treatment;\n* Inability or refusal to provide informed consent;\n* No health coverage\n* People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials;\n* People deprived of freedom by judicial or administrative decision;\n* People subject to legal protection, who cannot be included in clinical trials.","80 Years",{"count":591,"type":22},64,[25],"In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.",[201,595,596,200,597,598,599],"Cerebral Hypoxia","Brain Diseases","Aging","Cognitive Decline","Healthy Aging",{"date":495,"type":36},{"date":602,"type":36},"2021-10-13",{"date":551,"type":22},{"name":42,"class":43},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":17,"minAge":417,"maxAge":4,"enrollmentInfo":613,"targetDuration":615,"studyType":56,"phases":4,"briefSummary":616,"conditions":617,"keywords":619,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":110},"100609190","high-intensity-interval-training-versus-moderate-intensity-continuous-training-in-frail-elderly-100609190","NCT07211334","High Intensity Interval Training Versus Moderate Intensity Continuous Training in Frail Elderly","Comparison of the Effects of Different Exercise Modalities in Frail Elderly People Care Setting","EPAF","Inclusion Criteria:\n\n* Adults aged 70 or older;\n* Patients meeting at least 1 of 5 frailty criteria (Fried criteria; 2001);\n* Patient does not object to the analysis of anonymized data;\n* Person affiliated with social security;\n* Patient's ability to use an ergocycle safely;\n* Patients medically stable patients with no acute illness or recent decompensation that could be aggravated by exercise (at the physician's discretion).\n\nExclusion Criteria:\n\n* Unstable medical conditions that may be aggravated by physical activity (as determined by a physician)\n* Musculoskeletal disorders and severe neurocognitive conditions that make it impossible to safely use the ergocycle or participate in the exercise program\n* individuals participating in other interventional studies or who have recently participated in an interventional study that could influence the results of this study\n* Persons referred to in Articles L1121-5 to L1121-8 of the public health code (corresponds to all protected persons: pregnant women, women in labor, breastfeeding mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to legal protection measures)",{"count":614,"type":22},92,"6 Months","The assessment and systematic integration of physical activity into the care pathway of frail elderly people is essential to prevent loss of independence and improve the quality of life of this population. This project, which is part of routine care, aims to evaluate the practices and, in particular, the effects of different types of physical exercise currently in use at the Health and Sport Center of the Grenoble Alpes University Hospital. It therefore aims to optimize professional practices without changing the standard care provided to patients. Recommendations regarding intensity during cardiorespiratory endurance training sessions (moderate to high, taking into account emotional factors) are broad and vary greatly in their application depending on the facilities that work with older adults. This project aims to compare the exercise methods used on ergocycle at Health and Sport Center of Grenoble Alpes University Hospital: high-intensity interval training (HIIT) vs. moderate-intensity continuous training (MICT) to reverse the functional decline that occurs in frail older adults.",[618],"Frail Elderly",[620,621,622,623,624,625],"Frailty","Elderly","High Intensity Interval Training","Moderate Intensity Continuous Training","Motivation for Physical Activity","Support for Changing Behavior Regarding Physical Activity","2026-04-28",{"date":576,"type":36},{"date":629,"type":36},"2025-12-11",{"date":631,"type":22},"2028-02",{"name":42,"class":43},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":90,"sex":17,"minAge":563,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":642,"conditions":643,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":110},"100553114","validation-of-an-alzheimers-disease-marker-by-fecal-assay-of-amyloid-peptides-and-tau-proteins-100553114","NCT06481878","Validation of an Alzheimer's Disease Marker by Fecal Assay of Amyloid Peptides and Tau Proteins","Validation of a Diagnostic and\u002For Prognostic Marker for Alzheimer's Disease by Fecal Determination of Amyloid Peptides and Tau Proteins","FecAlz","Inclusion Criteria:\n\nFor subjects with Alzheimer's disease MA TCM (A+ T+):\n\n* Subjects diagnosed with AD according to IWG 2021 criteria\n* Subject at the stage of major cognitive impairment\n* At least 40 years of age\n* Presence of a caregiver or support person\n* No informed opposition\n\nFor subjects with AD TCm (A+ T+):\n\n* Subject diagnosed with AD according to IWG 2021 criteria\n* Subject at the stage of minor cognitive impairment\n* Minimum age 40\n* No informed opposition For subjects with minor or major cognitive impairment who do not have AD TC Non-AD LCR negative (A- T-)\n* Subject at stage of minor or major cognitive impairment\n* CSF negative (A-T-) for Alzheimer's disease biomarkers: A-T- according to ATN classification\n* Minimum age 40\n* No informed objection and TCm CSFdiscordant (A+ T-) or (A- T+):\n* Subject at stage of minor cognitive impairment\n* CSF discordant (A-T+ or A+T-) with Alzheimer's disease biomarkers\n* Minimum age 40\n* No informed opposition\n\nFor healthy volunteers (VS) :\n\n* No cognitive complaints\n* MMSE ≥ 26\n* CDR 0\n* Minimum age 40\n* No informed opposition\n\nExclusion Criteria:\n\nFor MA TCM (A+ T+), MA TCm (A+T+) and TC Non MA LCR negatif (A-T-) and TCm LCRdiscordant (A+ T-) or (A- T+):\n\n* Inability to understand search instructions or to give informed non-opposition\n* Absence of social security affiliation or plan\n* Persons covered by articles L1121-5 to L1121-8 of the CSP (legally protected adult, subject under administrative or judicial supervision)\n\nFor healthy volunteers:\n\n* Incapacity to understand research instructions or to give informed non-opposition\n* Persons covered by articles L1121-5 to L1121-8 of the CSP (legally protected adult, subject under administrative or judicial supervision)\n* Absence of social security affiliation or of such a scheme",{"count":55,"type":22},"Alzheimer's disease (AD) is the leading cause of dementia in humans, currently affecting almost one million people in France. It results from an irreversible degeneration of neurons responsible for a progressive decline in the main cognitive and memory functions due to a cerebral accumulation of plaques containing fibrillary amyloid peptide (Aβ) and neurofibrillary tangles composed of truncated, hyperphosphorylated tau protein (pTau).\n\nThere is currently no curative treatment for this disease in France. However, two treatments aimed at reducing beta-amyloid plaques in the brain have been approved by the U.S. Food and Drug Administration. The failure of the latest therapeutic strategies is largely due to the fact that the disease is diagnosed too late, starting with a long asymptomatic phase, which is the one that needs to be targeted in order to prevent irreversible neurodegenerative mechanisms.\n\nThe development of diagnostic tools is gradually making it possible to detect such a sequence, but this has its drawbacks (radioactive load, invasive procedure, cumbersome set-up).\n\nOver the last ten years, research has focused on the development of plasma or salivary markers. Although encouraging, these studies show either a lack of sensitivity or reproducibility, or a lack of specificity or precocity.\n\nThe expression of Aβ and Tau proteins has recently been demonstrated in the enteric nervous system and enterocytes. Intestinal Aβ is involved in various gut functions and regulation.\n\nWhat recent work by investigators demonstrates is the essential and hitherto unrecognized role of the gut-brain axis in maintaining brain homeostasis. In a mouse model of AD, the investigators have demonstrated a mechanism for intestinal elimination (clearance) of toxic brain forms of Tau and Aβ proteins, via the lymphatic network.\n\nThe clearance of cerebral Tau and Aβ proteins in the stool may constitute a reliable and powerful diagnostic signature of AD. Its study would represent a new, non-invasive and easily accessible technique for the early diagnosis of AD in humans.",[644],"Alzheimer Disease",{"date":576,"type":36},{"date":647,"type":36},"2024-10-11",{"date":649,"type":22},"2027-10-06",{"name":42,"class":43},""]